JP2023525298A5 - - Google Patents
Info
- Publication number
- JP2023525298A5 JP2023525298A5 JP2022567837A JP2022567837A JP2023525298A5 JP 2023525298 A5 JP2023525298 A5 JP 2023525298A5 JP 2022567837 A JP2022567837 A JP 2022567837A JP 2022567837 A JP2022567837 A JP 2022567837A JP 2023525298 A5 JP2023525298 A5 JP 2023525298A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- sequence
- antibody
- seq
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022309P | 2020-05-08 | 2020-05-08 | |
| US63/022,309 | 2020-05-08 | ||
| PCT/US2021/031541 WO2021226576A1 (en) | 2020-05-08 | 2021-05-10 | Sirp alpha and sirp beta 1 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525298A JP2023525298A (ja) | 2023-06-15 |
| JP2023525298A5 true JP2023525298A5 (cg-RX-API-DMAC7.html) | 2024-05-20 |
Family
ID=76197640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567837A Pending JP2023525298A (ja) | 2020-05-08 | 2021-05-10 | Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12503508B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4146699A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023525298A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20230017793A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115768795A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021269130A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3178038A1 (cg-RX-API-DMAC7.html) |
| GB (2) | GB2613259A (cg-RX-API-DMAC7.html) |
| IL (2) | IL297982A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202208430A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021226591A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023525298A (ja) | 2020-05-08 | 2023-06-15 | エレクトラ・セラピューティクス・インコーポレイテッド | Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用 |
| TW202330911A (zh) * | 2021-11-24 | 2023-08-01 | 日商雷格細胞股份有限公司 | 人類誘導性控制性t細胞及其製作方法 |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN117025547B (zh) * | 2023-10-08 | 2023-12-12 | 迈杰转化医学研究(苏州)有限公司 | 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用 |
| TW202523701A (zh) | 2023-10-19 | 2025-06-16 | 美商電子療法股份有限公司 | 用於治療癌症之sirp抗體 |
| TW202529810A (zh) | 2023-10-19 | 2025-08-01 | 美商電子療法股份有限公司 | 用於治療噬血球性淋巴組織細胞增生症之sirp抗體 |
| TW202547858A (zh) | 2024-04-22 | 2025-12-16 | 美商電子療法股份有限公司 | 用於治療愛潑斯坦—巴爾病毒感染之SIRPα及β抗體 |
| CN119192379B (zh) * | 2024-11-22 | 2025-01-28 | 四川省医学科学院·四川省人民医院 | 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015138600A2 (en) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| RU2764548C2 (ru) * | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| WO2018118887A1 (en) | 2016-12-22 | 2018-06-28 | Wake Forest University Health Sciences | Sirp-gamma targeted agents for use in the treatment of cancer |
| CN110300764A (zh) * | 2017-02-17 | 2019-10-01 | Ose免疫疗法 | 抗SIRPg抗体的新用途 |
| JP7160833B2 (ja) * | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
| PT3625259T (pt) * | 2017-05-16 | 2024-07-04 | Synthon Biopharmaceuticals Bv | Anticorpos anti-sirpalfa |
| CN111511766B (zh) * | 2017-10-13 | 2024-06-07 | Ose免疫疗法 | 修饰的抗SIRPa抗体及其应用 |
| CR20200566A (es) * | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| MX2021015937A (es) | 2019-06-24 | 2022-02-03 | Amgen Inc | Inhibicion de sirp-gamma para el tratamiento del cancer. |
| EP4110819A1 (en) | 2020-02-28 | 2023-01-04 | Apexigen, Inc. | Anti-sirpa antibodies and methods of use |
| JP2023525298A (ja) | 2020-05-08 | 2023-06-15 | エレクトラ・セラピューティクス・インコーポレイテッド | Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用 |
| EP4429768A2 (en) | 2021-11-10 | 2024-09-18 | Electra Therapeutics, Inc. | Sirp gamma antibodies and uses thereof |
| TW202529810A (zh) | 2023-10-19 | 2025-08-01 | 美商電子療法股份有限公司 | 用於治療噬血球性淋巴組織細胞增生症之sirp抗體 |
| TW202523701A (zh) | 2023-10-19 | 2025-06-16 | 美商電子療法股份有限公司 | 用於治療癌症之sirp抗體 |
-
2021
- 2021-05-10 JP JP2022567837A patent/JP2023525298A/ja active Pending
- 2021-05-10 IL IL297982A patent/IL297982A/en unknown
- 2021-05-10 CA CA3178038A patent/CA3178038A1/en active Pending
- 2021-05-10 TW TW110116827A patent/TW202208430A/zh unknown
- 2021-05-10 GB GB2218419.6A patent/GB2613259A/en not_active Withdrawn
- 2021-05-10 WO PCT/US2021/031605 patent/WO2021226591A1/en not_active Ceased
- 2021-05-10 US US17/923,778 patent/US12503508B2/en active Active
- 2021-05-10 CN CN202180033618.6A patent/CN115768795A/zh active Pending
- 2021-05-10 AU AU2021269130A patent/AU2021269130A1/en active Pending
- 2021-05-10 KR KR1020227042887A patent/KR20230017793A/ko active Pending
- 2021-05-10 WO PCT/US2021/031541 patent/WO2021226576A1/en not_active Ceased
- 2021-05-10 US US17/923,781 patent/US20230174648A1/en active Pending
- 2021-05-10 CA CA3177961A patent/CA3177961A1/en active Pending
- 2021-05-10 TW TW110116828A patent/TW202208431A/zh unknown
- 2021-05-10 AU AU2021267943A patent/AU2021267943A1/en active Pending
- 2021-05-10 KR KR1020227042951A patent/KR20230017219A/ko active Pending
- 2021-05-10 IL IL298024A patent/IL298024A/en unknown
- 2021-05-10 EP EP21730008.6A patent/EP4146699A1/en active Pending
- 2021-05-10 CN CN202180033623.7A patent/CN115768796A/zh active Pending
- 2021-05-10 EP EP21729164.0A patent/EP4146698A1/en active Pending
- 2021-05-10 GB GB2218421.2A patent/GB2613464A/en not_active Withdrawn
-
2024
- 2024-02-28 US US18/590,865 patent/US12187797B2/en active Active
- 2024-11-27 US US18/963,213 patent/US20250197492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230242648A1 (en) | Antibodies to integrin avb6 and use of same to treat cancer | |
| AU2016276751B2 (en) | CD123 antibodies and conjugates thereof | |
| US20210047404A1 (en) | Cd33 antibodies and use of same to treat cancer | |
| GB2613259A (en) | SIRP alpha and SIRP beta 1 antibodies and uses thereof | |
| WO2019144945A1 (en) | Anti-pd-l1 antibody and il-7 fusions | |
| US8545844B2 (en) | Humanized antibodies against human IL-22RA | |
| US20230080842A1 (en) | Tetravalent symmetric bispecific antibodies | |
| CN114728065A (zh) | 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 | |
| JP2024513921A (ja) | 抗cd122抗体及びその使用 | |
| WO2018117237A1 (ja) | 抗cd3抗体及び該抗体を含む分子 | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| CN119768425A (zh) | 抗-tl1a抗体及其使用方法 | |
| WO2021262791A1 (en) | High affinity antibodies targeting tau phosphorylated at serine 413 | |
| JP2023537078A (ja) | COVID-19を治療及び防止するためのSARS-CoV-2抗体 | |
| WO2021258337A1 (en) | Human monoclonal antibodies against tigit for immune related diseases | |
| JP2022527790A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2016163433A1 (ja) | 抗fgfr2抗体と他剤を含む組成物 | |
| JP2023525753A5 (cg-RX-API-DMAC7.html) | ||
| WO2025103425A1 (en) | Multispecific antibodies and uses thereof | |
| WO2024131849A1 (zh) | Cd38单克隆抗体及其应用 | |
| JP2020507338A (ja) | 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 | |
| WO2024218650A1 (en) | Lilrb1 and lilrb2 antibodies and methods of use thereof | |
| CN117715932A (zh) | 一种cdc平台抗体 | |
| HK40067877A (en) | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom |